Organoids cultured from patient-derived colorectal cancer cells have been used to demonstrate for the first time that tumors which have developed resistance to the full range of existing treatments, across chemotherapies, targeted therapies and immunotherapies, retain a requirement for Werner helicase (WRN) for survival.

A French study has demonstrated that the novel agonist anti-human ChemR23 monoclonal antibody (MAb) designated OSE-230 accelerated recovery from acute inflammation and triggered resolution of chronic inflammation in mice chronic colitis models, preventing fibrosis and reducing tumor development.

A Korean study led by Seoul National University scientists is the first to demonstrate that the human intestinal mucin-degrading bacterium, Akkermansia muciniphila, secretes a glucagon-like peptide-1 (GLP-1)-inducing protein, which significantly improved glucose homeostasis and ameliorated metabolic disease in mice.

Cachexia, Teresa Zimmers told the audience at the Annual Meeting of the American Association for Cancer Research (AACR), is "woefully understudied for the outsized impact it has on cancer patients." The condition, which is currently defined as weight loss and muscle wasting, is the direct cause of death in an estimated 25% to 30% of cancer patients. But it is the main subject of only 0.1% of research papers and 0.2% of clinical trials.

A splicing defect in the survival of motor neuron gene (SMN) leads to a deficiency of protein function that results in spinal muscular atrophy. It is the second most common autosomal recessive disease, occurring with a prevalence of 1 to as little as 6,000 births.